Cargando…

P1282: MOCRAVIMOD IMPROVES OVERALL SURVIVAL IN AML PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

Detalles Bibliográficos
Autores principales:	Medinger, Michael, Passweg, Jakob, Bucher, Christoph, Finke, Juergen, Schanz, Urs, Stylianou, Christos, Dertschnig, Simone, Souquières, Malika, Oehen, Stephan, Kueenburg, Elisabeth, Heim, Dominik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430530/ http://dx.doi.org/10.1097/01.HS9.0000972016.06838.fa

Ejemplares similares

Effect of pharmacokinetics and pharmacogenomics in adults with allogeneic hematopoietic cell transplantation conditioned with Busulfan
por: Seydoux, Claire, et al.
Publicado: (2023)

Busulfan-cyclophosphamide versus cyclophosphamide-busulfan as conditioning regimen before allogeneic hematopoietic cell transplantation: a prospective randomized trial
por: Seydoux, Claire, et al.
Publicado: (2020)

Optimal Treatment Duration of Pseudomonas aeruginosa Infections in Allogeneic Hematopoietic Cell Transplant Recipients
por: Olearo, Flaminia, et al.
Publicado: (2020)

Influence of HLA-DPB1 mismatches on outcome after allogeneic hematopoietic stem cell transplantation
por: Hunziker, Mireille, et al.
Publicado: (2021)

Impact of busulfan pharmacokinetics on outcome in adult patients receiving an allogeneic hematopoietic cell transplantation
por: Seydoux, Claire, et al.
Publicado: (2022)

Allogeneic hematopoietic stem cell transplantation in non‐Hodgkin lymphoma in Switzerland, 30 years of experience: Sooner is better
por: Rebmann, Ekaterina, et al.
Publicado: (2022)

Low Incidence of hepatic sinusoidal obstruction syndrome/veno-occlusive disease in adults undergoing allogenic stem cell transplantation with prophylactic ursodiol and low-dose heparin
por: Stutz, Lina, et al.
Publicado: (2022)

Clinical Presentation of the c.3844T>C (p.Trp1282Arg, W1282R) Variant in Russian Cystic Fibrosis Patients
por: Petrova, Nika V., et al.
Publicado: (2020)

Optimized cyclosporine starting dose may reduce risk of acute GvHD after allogeneic hematopoietic cell transplantation: a single-center cohort study
por: Héritier, Jérémie, et al.
Publicado: (2022)

Feasibility and efficacy of salvage allogeneic stem cell transplantation in AML patients relapsing after autologous stem cell transplantation
por: Shumilov, Evgenii, et al.
Publicado: (2021)

External Validation of the Revised Pretransplant Assessment of Mortality Score in Allogeneic Hematopoietic Cell Transplantation: A Cohort Study
por: Fattinger, Nicolas, et al.
Publicado: (2022)

Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma in Switzerland, 20 years of experience: 2001–2020
por: Simeunovic, Helena, et al.
Publicado: (2022)

Very long-term follow-up of aplastic anemia treated with immunosuppressive therapy or allogeneic hematopoietic cell transplantation
por: Drexler, Beatrice, et al.
Publicado: (2020)

Characterization of engraftment dynamics in myelofibrosis after allogeneic hematopoietic cell transplantation including novel conditioning schemes
por: Jungius, Sarah, et al.
Publicado: (2023)

P1379: OPTIMIZATION OF FLUDARABINE PHARMACOKINCETICS TO REDUCE THE RELAPSE INCIDENCE IN AML PATIENTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
por: Thavayogarajah, T., et al.
Publicado: (2022)

Possible Reactivation of SARS-CoV-2 in a Patient with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: a Case Report
por: Dalla Via, Vera, et al.
Publicado: (2021)

Angiogenesis in myeloproliferative neoplasms, new markers and future directions
por: Medinger, Michael, et al.
Publicado: (2014)

Robust Stimulation of W1282X-CFTR Channel Activity by a Combination of Allosteric Modulators
por: Wang, Wei, et al.
Publicado: (2016)

The Elephant in The Room: AML Relapse Post Allogeneic Hematopoietic Cell Transplantation
por: Abou Dalle, Iman, et al.
Publicado: (2022)

1282. Ceftolozane/Tazobactam Use in Critically Ill Patients Receiving Intermittent or Continuous Renal Replacement Therapy
por: Henry, Molly, et al.
Publicado: (2021)

P1282: DISEASE-SPECIFIC U1 SPLICEOSOMAL RNA MUTATIONS IN MATURE B-CELL NEOPLASMS
por: Nadeu, F., et al.
Publicado: (2022)

Maintenance therapy for AML after allogeneic HCT
por: Nayak, Rahul K., et al.
Publicado: (2022)

Transient paraproteinemia after allogeneic hematopoietic stem cell transplantation is an underexplored phenomenon associated with graft versus host disease
por: Widmer, Corinne C., et al.
Publicado: (2017)

Novel therapeutic options in Acute Myeloid Leukemia
por: Medinger, Michael, et al.
Publicado: (2016)

Editorial: The Elephant in the Room: AML Relapse After Allogeneic Hematopoietic Cell Transplantation
por: Battipaglia, Giorgia, et al.
Publicado: (2022)

Generalist in allogeneic hematopoietic stem cell transplantation for MDS or AML: Epigenetic therapy
por: Yang, Guancui, et al.
Publicado: (2022)

Bridging Strategies to Allogeneic Transplant for Older AML Patients
por: Hecker, Judith, et al.
Publicado: (2018)

Effects of T-Cell Depletion on Allogeneic Hematopoietic Stem Cell Transplantation Outcomes in AML Patients
por: Hobbs, Gabriela Soriano, et al.
Publicado: (2015)

1282. Detection of HIV Transmitted Drug Resistance by Next-Generation Sequencing in a CRF01_AE Predominant Epidemic
por: Salvana, Edsel Maurice, et al.
Publicado: (2018)

Prime editing-mediated correction of the CFTR W1282X mutation in iPSCs and derived airway epithelial cells
por: Li, Chao, et al.
Publicado: (2023)

Pathogenesis of Acquired Aplastic Anemia and the Role of the Bone Marrow Microenvironment
por: Medinger, Michael, et al.
Publicado: (2018)

A diffuse rash in a patient after allogeneic hematopoietic stem cell transplant for AML
por: Ferdjallah, Asmaa, et al.
Publicado: (2020)

Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation
por: Joshi, Maansi, et al.
Publicado: (2021)

1282. Evaluation of Opportunities for Implementing OVIVA Criteria on Patients with Bone and Joint Infections (BJIs) in Outpatient Parenteral Antimicrobial Therapy (OPAT)
por: Crawford, Garrett, et al.
Publicado: (2023)

Prognostic prediction of novel risk scores (AML-DRG and AML-HCT-CR) in acute myeloid leukemia patients with allogeneic hematopoietic stem cell transplantation
por: Cao, Weijie, et al.
Publicado: (2022)

Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort
por: Brune, Magdalena M., et al.
Publicado: (2021)

Real-world outcomes in elderly ALL patients with and without allogeneic hematopoietic stem cell transplantation: a single-center evaluation over 10 years
por: Hofer, Kevin D., et al.
Publicado: (2022)

MRD as Biomarker for Response to Donor Lymphocyte Infusion after Allogeneic Hematopoietic Cell Transplantation in Patients with AML
por: Teich, Katrin, et al.
Publicado: (2023)

Addition of venetoclax to myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in high-risk AML
por: Cao, Xing-yu, et al.
Publicado: (2023)

Corrigendum to “Effect of the COVID-19 Pandemic on Kidney Transplant and on Chronic Dialysis Patients” [Transplantation Proceedings 54/5 (2022) 1282–1285]
por: Amsei, Thamiris Quiqueto Marinelli, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_t6ctg999prckd4h0vdbli6f1k6